1. Introduction

Biotechnology export control rules are laws and regulatory mechanisms that govern the international transfer of biological materials, genetically modified organisms, pathogens, toxins, laboratory equipment, biotechnology software, technical data and related research. Their purpose is to permit legitimate scientific research and commercial trade while preventing the proliferation of biological weapons, misuse of dual-use technologies and threats to national security.

Biotechnology exports may include:

Biological agents, toxins and certain microorganisms.

Genetically engineered organisms and biological samples.

Vaccines, diagnostic materials and pharmaceutical intermediates.

Fermentation systems, bioreactors and specialised laboratory equipment.

Genetic engineering technologies, technical know-how, software and research data.

Not every biotechnology product is controlled. Whether an export requires a licence depends on the specific item, its technical characteristics, destination, intended end use, recipient and the applicable country's laws.

For example, exporting an ordinary diagnostic kit may be treated differently from exporting a controlled pathogen, specialised biological production equipment or technical information that could contribute to a biological weapons programme.

2. Objectives and legal foundations

The principal objectives of biotech export controls are:

Non-proliferation: preventing biological weapons and related capabilities from reaching unauthorised actors.

National security: restricting transfers that may threaten domestic or international security.

Dual-use oversight: regulating technologies that have both peaceful and harmful applications.

Responsible scientific cooperation: allowing legitimate research while screening sensitive transfers.

International compliance: implementing treaty obligations and coordinated export-control standards.

Accountability: ensuring that exporters, research institutions, intermediaries and end users comply with applicable licensing conditions.

A central concept is dual-use technology. A biological process or instrument may support vaccine development, agricultural research or public health while also having potential military or prohibited applications.

At the international level, important instruments include the Biological Weapons Convention (BWC), United Nations Security Council Resolution 1540, and the Australia Group's coordinated export-control arrangements. These operate alongside national legislation; they do not create an identical licensing system in every country.

Ministry of External Affairs+1

3. Biotech export control law in India

For Indian exporters, the principal framework is the Foreign Trade (Development and Regulation) Act, 1992, the Foreign Trade Policy (FTP) 2023 as amended, the Handbook of Procedures, and the SCOMET control list. Other laws may apply depending on the material and activity.

A. SCOMET: Special Chemicals, Organisms, Materials, Equipment and Technologies

India's SCOMET framework regulates specified dual-use goods, software and technology. Category 2 is particularly relevant because it covers specified microorganisms and toxins. Related equipment, processing technologies and technical information may also fall under other categories or controls, depending on their classification.

The principal authorities include:

Directorate General of Foreign Trade (DGFT): handles export authorisations for relevant SCOMET categories, including Category 2.

Department of Atomic Energy (DAE): handles designated nuclear-related items.

Department of Defence Production: handles relevant items on the munitions list.

The classification and licensing authority must be verified against the applicable control-list entry, rather than assumed solely from the product's commercial description.

DGFT Content+1

B. Principal Indian statutes

The WMD Act is particularly important where transfers involve controlled technology or activities connected with weapons of mass destruction. Its restrictions must be read alongside the relevant export-control notifications and other applicable legislation.

India+2

C. The current control list must be checked

A significant compliance point is that the SCOMET list is periodically revised. DGFT Notification No. 31/2025-26, dated 23 September 2025, amended Appendix 3 of Schedule 2 and provided for the changes to take effect 30 days after issuance.

Consequently, exporters should consult the applicable amended list and current Handbook of Procedures rather than relying on an older list or a historical classification.

Gazette Notification PDF+1

4. International legal framework

Biological Weapons Convention - Meeting of States Parties (2019) | United Nations

A. Biological Weapons Convention (BWC)

The BWC prohibits the development, production, acquisition, stockpiling, retention and transfer of biological and toxin weapons within the scope of the Convention. Article III addresses transfers and assistance connected with prohibited purposes. Article X protects peaceful cooperation and exchanges for biological purposes consistent with the Convention.

The Convention is not itself a universal shipment-by-shipment licensing code; states implement its obligations through domestic law.

RSF complains to UN about coronavirus press freedom violations | RSF

B. UN Security Council Resolution 1540 (2004)

Resolution 1540 requires states to adopt and enforce measures to prevent non-state actors from acquiring weapons of mass destruction and related materials. It supports domestic controls over sensitive materials, equipment and associated technologies.

PPT - Chemical Dual-Use Awareness PowerPoint Presentation, free download - ID:5500860

C. Australia Group

The Australia Group coordinates export-control approaches for chemicals, biological agents, equipment and related technologies that could contribute to chemical or biological weapons programmes. Participating states implement controls through their own national legislation.

These instruments aim to balance non-proliferation with legitimate medical, agricultural, industrial and scientific cooperation.

The Australia Group+2

5. Case laws and enforcement precedents

Reported Indian judgments directly interpreting biotechnology export-control licensing are relatively limited. Therefore, it is important to distinguish Indian judicial decisions concerning exports of biological or pharmaceutical materials from foreign administrative enforcement cases that directly address biological export controls.

Case 1: Bayer Corporation v. Union of India & Ors. (2014)

Delhi High Court · 5 November 2014 · 2014:DHC:5716

Facts: The dispute concerned Sorafenib, a patented pharmaceutical active ingredient. Natco sought to export a limited quantity for research and regulatory studies abroad, raising questions about the scope of Section 107A of the Patents Act, 1970, and the restrictions associated with its compulsory licence.

Legal issue: Whether exporting an active pharmaceutical ingredient for foreign regulatory studies could qualify for the statutory patent-law exception.

Significance: The case illustrates the distinction between patent-law restrictions and export-control requirements. Patent-law permission or an exception does not automatically establish compliance with SCOMET, customs, biosafety or destination-country rules.

Relevance to biotech exports: Pharmaceutical ingredients, clinical-study samples and biological research materials may be subject to several independent legal regimes. Each must be assessed separately.

Cornelia – Judgment+1

Case 2: Princeton University export-control settlement (2021)

U.S. Department of Commerce, Bureau of Industry and Security · 2 February 2021

Facts: The Bureau of Industry and Security (BIS) resolved allegations that Princeton University had made 37 unlicensed exports of animal-pathogen strains and recombinants to overseas research institutions between 2013 and 2018.

Outcome: Princeton agreed to a US$54,000 administrative settlement and external and internal audits of its export-compliance programme. The university had voluntarily disclosed potential violations and cooperated with the investigation.

Legal principle: Scientific purpose and academic status do not automatically exempt biological materials from export licensing. Research institutions must evaluate the applicable controls before international shipment.

This was an administrative settlement, not a judicial precedent establishing a binding court rule.

Bureau of Industry and Security

Case 3: Indiana University export-control settlement (2024)

U.S. Department of Commerce, Bureau of Industry and Security · 24 June 2024

Facts: Indiana University's Bloomington Drosophila Stock Center exported genetically modified fruit flies containing transgenes carrying ricin A-subunit sequences to research institutions in 16 countries. BIS alleged 42 export-control violations involving shipments made without required licences.

Outcome: The university admitted the conduct described in the charging allegations and reached a settlement. The order imposed export-compliance training, educational presentations and a one-year suspended denial order for certain exports. Voluntary disclosure and cooperation contributed to the resolution.

Legal principle: The regulatory classification of an exported biological research material may depend on its genetic characteristics and associated controlled components, not merely on whether the material is ordinarily used for harmless basic research.

Relevance to India: Indian research institutions should similarly assess the precise SCOMET classification and applicable end-use restrictions before shipping genetically modified organisms or other controlled biological materials. The US decision does not itself determine Indian law.

Bureau of Industry and Security

Case 4: United States export-control restrictions on biological weapons end uses

Export Administration Regulations · 15 C.F.R. § 744.4

This is a regulatory provision rather than a court case.

Under § 744.4, certain exports, reexports and in-country transfers of items subject to the US Export Administration Regulations (EAR) are prohibited without a licence when the exporter knows that the items will be used in specified chemical or biological weapons activities.

Licensing decisions can consider the proposed end use, the significance of the transfer, the recipient country's non-proliferation credentials and assurances against prohibited use.

Legal significance: Even where an item is not ordinarily treated as a controlled export, end-use restrictions may still apply. The EAR's precise scope depends on whether the item and transaction are subject to US jurisdiction.

Bureau of Industry and Security+1

6. Comparative analysis of the precedents

The distinction matters academically: settlements and regulations are valuable evidence of enforcement practice, but they should not be cited as though they were binding Indian court judgments.

7. Licensing procedure for biotechnology exports from India

An exporter dealing with potentially controlled biological materials should follow a documented compliance process.

Step 1 — Classify the item

Identify the biological material, its characteristics, the relevant technical specifications and the applicable SCOMET entry.

Step 2 — Determine authorisation requirements

Check the current DGFT control list, the applicable Handbook of Procedures, any relevant exemptions and other statutory permissions.

Step 3 — Screen the transaction

Verify the recipient, ultimate end user, destination, intended use, intermediaries and any applicable sanctions or end-use restrictions.

Step 4 — Apply for authorisation where required

Submit the applicable DGFT application and supporting information, including technical classification and end-use documentation.

Step 5 — Verify all conditions before shipment

Confirm that the authorisation covers the actual item, recipient, destination, quantity and proposed transaction. Obtain any additional biosafety, transport or customs permissions that apply.

Step 6 — Maintain compliance records

Retain classification decisions, licences, shipping records, end-user undertakings and relevant correspondence for the periods required by applicable law.

India's official DGFT website and the Ministry of External Affairs' Strategic Trade Controls and SCOMET resource page are useful starting points for checking the applicable control list and authorisation requirements.

Ministry of External Affairs+1

8. Liability and penalties for violations

Unauthorised exports can result in multiple forms of liability, depending on the applicable statute and the facts.

Administrative action: Suspension, cancellation or other restrictions affecting export authorisations.

Customs enforcement: Detention, seizure or confiscation where the relevant statutory conditions are met.

Financial penalties: Monetary penalties under applicable export-control or customs provisions.

Criminal liability: Prosecution where the elements of an applicable criminal offence are established.

Commercial consequences: Contract termination, loss of export privileges, reputational damage and disruption to international research partnerships.

In India, the precise consequences must be determined under the relevant provisions of the Foreign Trade (Development and Regulation) Act, 1992, the WMD Act, the Customs Act and any other applicable legislation. A classification error does not automatically establish every element of a criminal offence; the statutory requirements and available defences must be assessed individually.

The Princeton and Indiana University settlements demonstrate that overseas enforcement authorities can take action against research institutions for unlicensed biological exports, even where the items have legitimate research applications.

Bureau of Industry and Security+1

9. Legal defences and compliance arguments

Depending on the jurisdiction and facts, an exporter or research institution may rely on the following arguments.

1. Incorrect classification: The material does not meet the technical description or thresholds of the controlled entry.

2. Applicable exemption: A statutory exemption or licence exception covers the specific transaction, subject to all relevant conditions.

3. Valid authorisation: The export was covered by a valid licence, and its conditions were satisfied.

4. Lack of a required legal element: The evidence does not establish an element required for the alleged violation, such as a relevant knowledge requirement where the offence requires one.

5. Procedural or jurisdictional defects: The authority acted outside its powers or failed to follow a legally mandatory procedure, where that defect is material under the applicable law.

6. Mitigation: Prompt voluntary disclosure, cooperation, corrective action and effective compliance controls may reduce enforcement consequences where the applicable regime permits.

These are potential arguments, not guaranteed defences. For example, the Princeton and Indiana University settlements show the potential value of voluntary disclosure, but they do not establish that disclosure automatically eliminates liability.

Bureau of Industry and Security+1

10. Emerging legal challenges

Biotechnology export controls face several continuing challenges:

Synthetic biology: Determining how controls apply to engineered biological materials and newly developed technologies.

Digital sequence information: Distinguishing controlled technical transfers from ordinary publication, open scientific data and other forms of information exchange.

Cloud laboratories and remote access: Assessing when cross-border technical assistance or access to controlled technology becomes a regulated transfer.

International research collaboration: Reconciling non-proliferation obligations with scientific freedom, public health and legitimate research.

Artificial intelligence in biotechnology: Determining how existing controls apply when AI-assisted tools facilitate the design or use of sensitive biological technologies.

Rapidly changing control lists: Ensuring that institutional procedures keep pace with amendments to national export rules.

The legal analysis must be transaction-specific. A scientific publication, physical biological sample and controlled technical dataset may be treated differently under the same national regime.

11. Conclusion

Biotech export control rules form a specialised area of trade, public international, administrative and national-security law. In India, the SCOMET framework—particularly Category 2 for specified microorganisms and toxins—is central to the analysis, alongside the Foreign Trade (Development and Regulation) Act, the WMD Act and other applicable laws.

The most important lessons from the cases and enforcement precedents are that legitimate scientific intent does not automatically eliminate licensing obligations, the precise technical classification matters, and voluntary disclosure may help mitigate enforcement outcomes without necessarily removing liability.

For academic legal writing, the strongest approach is to distinguish binding statutory provisions and judicial decisions from international guidelines and administrative settlements, and to analyse each authority within its proper jurisdiction.

Further research

A useful next step would be to develop this into a case-law research paper focused specifically on Indian SCOMET Category 2, statutory provisions, reported judgments and enforcement mechanisms, with citations to primary legal sources.